Drug Trial Radar · NCT05565560
A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque Psoriasis
Last checked: Nov 20, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
21
Actual
Start
Jan 25, 2023
Primary completion
Nov 20, 2025
Study completion Sep 3, 2026
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Oct 4, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the efficacy of apremilast in children and adolescents (ages 6 through 17 years) with moderate to severe plaque psoriasis.
Conditions
- Plaque Psoriasis
Interventions
ApremilastDrug
Oral tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Achievement of a static Physician Global Assessment (sPGA) score of clear (0) or almost clear (1) with at least 2 points reduction from baseline at Week 16Time frame: Week 16
Locations
29 sites in 1 country. Site status is shown where the registry gives one.
Tokyo Medical University Hospital
Shinjyuku-ku, Japan
Nagoya City University Hospital
Nagoya, Aichi-ken, Japan
Fukuoka University Hospital
Fukuoka, Fukuoka, Japan
Hospital of the University of Occupational and Environmental Health, Japan
Kitakyushu-shi, Fukuoka, Japan
Kurume University Hospital
Kurume-shi, Fukuoka, Japan
Fukushima Medical University Hospital
Fukushima, Fukushima, Japan
Gifu University Hospital
Gifu, Gifu, Japan
Gunma University Hospital
Maebashi, Gunma, Japan
Takagi Dermatological Clinic
Obihiro-shi, Hokkaido, Japan
Hokkaido University Hospital
Sapporo, Hokkaido, Japan
Kanazawa Medical University Hospital
Kahoku-gun, Ishikawa-ken, Japan
Takeoka Dermatology Clinic
Marugame-shi, Kagawa-ken, Japan
Takamatsu Red Cross Hospital
Takamatsu, Kagawa-ken, Japan
Saruwatari Dermatology Clinic
Kagoshima, Kagoshima-ken, Japan
Tokai University Hospital
Isehara-shi, Kanagawa, Japan
St Marianna University Hospital
Kawasaki-shi, Kanagawa, Japan
University Hospital Kyoto Prefectural University of Medicine
Kyoto, Kyoto, Japan
Shinshu University Hospital
Matsumoto-shi, Nagano, Japan
Nagasaki University Hospital
Nagasaki, Nagasaki, Japan
University of the Ryukyus Hospital
Ginowan-shi, Okinawa, Japan
Kansai Medical University Hospital
Hirakata-shi, Osaka, Japan
Nippon Life Hospital
Osaka, Osaka, Japan
Kindai University Hospital
Osakasayama-shi, Osaka, Japan
Dokkyo Medical University Hospital
Shimotsuga-gun, Tochigi, Japan
Sugai Dermatology Park Side Clinic
Utsunomiya, Tochigi, Japan
St Lukes International Hospital
Chuo-ku, Tokyo, Japan
Mita Dermatology Clinic
Minato-ku, Tokyo, Japan
Seibo International Catholic Hospital
Shinjuku-ku, Tokyo, Japan
Teikyo University Hospital
tabashi City, Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.